RNAC
Price
$8.63
Change
-$0.83 (-8.77%)
Updated
Jul 13 closing price
Capitalization
253.27M
24 days until earnings call
Intraday BUY SELL Signals
XOMAP
Price
$25.00
Change
+$0.02 (+0.08%)
Updated
Jul 13 closing price
Capitalization
N/A
Intraday BUY SELL Signals
Interact to see
Advertisement

RNAC vs XOMAP

RNAC vs XOMAP Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
RNAC vs. XOMAP commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNAC is a Buy and XOMAP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (RNAC: $8.63 vs. XOMAP: $24.98)
Brand notoriety: RNAC and XOMAP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RNAC: 42% vs. XOMAP: 143%
Market capitalization -- RNAC: $253.27M vs. XOMAP: $0
RNAC [@Biotechnology] is valued at $253.27M. XOMAP’s [@Biotechnology] market capitalization is $0. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RNAC’s FA Score shows that 0 FA rating(s) are green whileXOMAP’s FA Score has 1 green FA rating(s).

  • RNAC’s FA Score: 0 green, 5 red.
  • XOMAP’s FA Score: 1 green, 4 red.
According to our system of comparison, RNAC is a better buy in the long-term than XOMAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RNAC’s TA Score shows that 5 TA indicator(s) are bullish while XOMAP’s TA Score has 6 bullish TA indicator(s).

  • RNAC’s TA Score: 5 bullish, 5 bearish.
  • XOMAP’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, XOMAP is a better buy in the short-term than RNAC.

Price Growth

RNAC (@Biotechnology) experienced а -16.54% price change this week, while XOMAP (@Biotechnology) price change was +0.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.

Reported Earning Dates

RNAC is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (-3.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNAC YTD gains are higher at: 19.695 vs. XOMAP (-1.008). XOMAP has higher annual earnings (EBITDA): 50.2M vs. RNAC (-88.9M). RNAC has more cash in the bank: 119M vs. XOMAP (93.3M). RNAC has less debt than XOMAP: RNAC (11.9M) vs XOMAP (125M). XOMAP has higher revenues than RNAC: XOMAP (7.65M) vs RNAC (1.78M).
RNACXOMAPRNAC / XOMAP
Capitalization253MN/A-
EBITDA-88.9M50.2M-177%
Gain YTD19.695-1.008-1,953%
P/E Ratio1.98N/A-
Revenue1.78M7.65M23%
Total Cash119M93.3M128%
Total Debt11.9M125M10%
FUNDAMENTALS RATINGS
RNAC: Fundamental Ratings
RNAC
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
44
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RNACXOMAP
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
6%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
18%
Momentum
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
27%
MACD
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
8%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
25%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
14%
Advances
ODDS (%)
Bullish Trend 21 days ago
82%
Bullish Trend 22 days ago
25%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 28 days ago
19%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
9%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
20%
View a ticker or compare two or three
Interact to see
Advertisement
RNAC
Daily Signal:
Gain/Loss:
XOMAP
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTOR0.700.01
+2.00%
Citius Oncology Inc
RMNI4.770.05
+1.06%
Rimini Street
BMRN59.200.08
+0.14%
BioMarin Pharmaceutical
CHSCN24.90-0.05
-0.20%
CHS
SGRY15.98-0.42
-2.56%
Surgery Partners

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with TAOX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-8.77%
TAOX - RNAC
91%
Closely correlated
-2.90%
PALI - RNAC
81%
Closely correlated
-3.57%
NKTX - RNAC
44%
Loosely correlated
-6.06%
EDIT - RNAC
44%
Loosely correlated
-3.07%
XENE - RNAC
41%
Loosely correlated
-1.74%
More

XOMAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, XOMAP has been loosely correlated with AMLX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if XOMAP jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XOMAP
1D Price
Change %
XOMAP100%
+0.08%
AMLX - XOMAP
51%
Loosely correlated
-2.03%
CGEN - XOMAP
31%
Poorly correlated
-3.77%
RNAC - XOMAP
29%
Poorly correlated
-8.77%
MRKR - XOMAP
28%
Poorly correlated
-3.31%
NBP - XOMAP
26%
Poorly correlated
-2.11%
More